A Better COVID Treatment for the Immunocompromised? Yale School of Medicine

A Better COVID Treatment for the Immunocompromised? Yale School of Medicine

A combination of two antiviral compounds may be a promising alternative to Paxlovid when treating COVID-19 in immunocompromised patients, according to Karen S. Anderson, PhD, professor of pharmacology and of molecular biophysics & biochemistry at Yale School of Medicine. Read the news.

The information provided by EDS S.H.A.R.E. and EDS Joint Effort is not medical advice. It is intended for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding any medical condition. EDS Joint Effort, its producers, and its contents are not liable for any actions taken based on the information provided, and all users agree to hold harmless EDS Joint Effort and all products, producers from any claims arising from the use of the information provided. This information is not designed to replace a physician’s independent judgment about the appropriateness or risks for a given patient. Always consult your doctor about your medical conditions. EDS S.H.A.R.E. does not provide medical advice, diagnosis or treatment. Use of the site is conditional upon your acceptance of our Terms of Use and Privacy Policy as stated.